Protagenic Therapeutics has two main collaborations:

The University of Toronto, and the Lab of David Lovejoy, Ph.D.

collaboration-lab-700

Technology born in Toronto, Canada, applicable all over the globe.

 

Protagenic Therapeutics owns an exclusive, worldwide license to commercialize technology discovered at the University of Toronto. The company-university relationship is one of the great assets of the company.

 

Protagenic Therapeutics Management believes that a collaboration can be a mutually-beneficial process for both a for-profit biotechnology company and a university. The company gains access to fundamental science that may contain a platform technology with important patient benefit implications. The university gains an outlet for fundamental research to find a foothold in the commercial sphere; which can have an edifying and validating impact on a substantial number of researchers who otherwise might feel partially constrained. Indeed, this is the context in which Protagenic Therapeutics pursues and will pursue all of its collaborations. Its first and central collaboration with the University of Toronto gave the company its first main product program. Management believes that this relationship may turn out to be extraordinarily beneficial for both partners.

Mutually-beneficial process for both a for-profit biotechnology company and a university.